-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
-
Summary
-
Kiniksa Pharmaceuticals International, plc quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q2 2021 to Q3 2024.
- Kiniksa Pharmaceuticals International, plc Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending September 30, 2024 was $24.9M, a 718% increase year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)